The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS)
owing to the approval of a number of new drugs with very distinct mechanisms of action. All …

Nocardiosis is an infectious disease caused by the gram-positive bacterium Nocardia spp.
Although it is commonly accepted that exposure to Nocardia is almost universal, only a small …

Alemtuzumab is a humanized monoclonal antibody approved for the treatment of relapsing-
remitting multiple sclerosis (RRMS), given as two annual courses on five consecutive days …

Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative
disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing …

Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5
consecutive days at core study baseline and on 3 consecutive days 12 months later …

Multiple sclerosis treatment faces tremendous changes as a result of the approval of new
medications. The new medications have differing safety considerations and risks after long …

The risk of infection associated with immunomodulatory or immunosuppressive disease-
modifying drugs (DMDs) in patients with multiple sclerosis (MS) has been increasingly …

Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52
antigen, and has been found to be a powerful treatment for relapsing remitting multiple …

Introduction: Alemtuzumab is a monoclonal anti CD-52 antibody recently approved for use in
relapsing-remitting multiple sclerosis (MS). Given that the targeted antigen is primarily …